In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Urogen Pharma (URGN – Research Report), with a price target of $55.00.
Ram Selvaraju has given his Buy rating due to a combination of factors that highlight the promising potential of Urogen Pharma’s UGN-102. The recent data presented at the American Urological Association 2025 Annual Meeting showcased the long-term efficacy and safety of UGN-102, particularly its ability to maintain a clinically meaningful response duration of 24.2 months in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. This durability is significant, especially for patients who have undergone multiple prior transurethral resection of bladder tumor procedures, suggesting a strong case for FDA approval and subsequent market success.
Additionally, the quality-of-life outcomes reported across several clinical trials, including OPTIMA II, ATLAS, and ENVISION, indicate that UGN-102 does not adversely affect patients’ quality of life. The treatment was shown to maintain high levels of function and low symptom burden without causing clinically significant declines. These positive clinical and patient-reported outcomes support the potential for UGN-102 to achieve robust market uptake, justifying the Buy rating and the 12-month target price of $55 per share.
Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Vanda, and Niagen Bioscience. According to TipRanks, Selvaraju has an average return of 0.0% and a 34.61% success rate on recommended stocks.
In another report released on April 17, Guggenheim also reiterated a Buy rating on the stock with a $40.00 price target.